The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
COVID‐19 and Toll‐Like Receptor 4 (TLR4): SARS‐CoV‐2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation
Open accessAbstract
Causes of mortality from COVID‐19 include respiratory failure, heart failure, and sepsis/multiorgan failure. TLR4 is an innate immune receptor on the cell surface that recognizes pathogen‐associated molecular patterns (PAMPs) including viral proteins and triggers the production of type I interferons and proinflammatory cytokines to combat infection. It is expressed on both immune cells and tissue‐resident cells. ACE2, the reported entry receptor for SARS‐CoV‐2, is only present on ~1‐2% of the cells in the lungs or has a low pulmonary expression, and recently, the spike protein has been proposed to have the strongest protein‐protein interaction with TLR4. Here, we review and connect evidence for SARS‐CoV‐1 and SARS‐CoV‐2 having direct and indirect binding to TLR4, together with other viral precedents, which when combined shed light on the COVID‐19 pathophysiological puzzle. We propose a model in which the SARS‐CoV‐2 spike glycoprotein binds TLR4 and activates TLR4 signalling to increase cell surface expression of ACE2 facilitating entry. SARS‐CoV‐2 also destroys the type II alveolar cells that secrete pulmonary surfactants, which normally decrease the air/tissue surface tension and block TLR4 in the lungs thus promoting ARDS and inflammation. Furthermore, SARS‐CoV‐2‐induced myocarditis and multiple‐organ injury may be due to TLR4 activation, aberrant TLR4 signalling, and hyperinflammation in COVID‐19 patients. Therefore, TLR4 contributes significantly to the pathogenesis of SARS‐CoV‐2, and its overactivation causes a prolonged or excessive innate immune response. TLR4 appears to be a promising therapeutic target in COVID‐19, and since TLR4 antagonists have been previously trialled in sepsis and in other antiviral contexts, we propose the clinical trial testing of TLR4 antagonists in the treatment of severe COVID‐19. Also, ongoing clinical trials of pulmonary surfactants in COVID‐19 hold promise since they also block TLR4.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341 · cited 1×
“Both SARS-CoV-2 and SARS-CoV-1 use angiotensin converting enzyme 2 (ACE2) as an entry receptor in humans, via binding of their outer surface spike S protein [8, 9].”
COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses
Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.03.005 · Cited by 3,536
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Yang, Y., Li, S., Yang, Q., Shi, Y., Zheng, M., Liu, Y., Chen, F., Song, G., Xu, H., Wan, T., et al. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000358696 · Cited by 3,253
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
COVID-19 and the cardiovascular system
Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y., & Xie, X. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0360-5 · Cited by 2,970
Karin, M., Liu, Z.-G., & Zandi, E. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80068-3 · Cited by 2,893
Antiviral Actions of Interferons
Samuel, C. E. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.778-809.2001 · Cited by 2,743
Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China
Wu, A., Peng, Y., Huang, B., Ding, X., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.02.001 · Cited by 2,361
Zou, X., Chen, K., Zou, J., Han, P., Hao, J., & Han, Z. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0754-0 · Cited by 2,287
Ziegler, C. G. K., Allon, S. J., Nyquist, S. K., Mbano, I. M., Miao, V. N., Tzouanas, C. N., Cao, Y., Yousif, A. S., Bals, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.035 · Cited by 2,284
Puntmann, V. O., Carerj, M. L., Wieters, I., Fahim, M., Arendt, C., Hoffmann, J., Shchendrygina, A., Escher, F., Vasa-Nicotera, M., Zeiher, A. M., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.3557 · Cited by 2,208
Longitudinal analyses reveal immunological misfiring in severe COVID-19
Lucas, C., Wong, P., Klein, J., Castro, T. B. R., Silva, J., Sundaram, M., Ellingson, M. K., Mao, T., Oh, J. E., Israelow, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2588-y · Cited by 2,074
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045 · cited 1×
“Recent studies have found that the production of IL-1β, IL-18, TNF-α, and IL-6 was high in severe COVID-19 patients especially those with severe respiratory failure and are linked to the cytokine storm [130, 136]; these cytokines are downstream of the TLR4 canonical MyD88dependent pathway.”
Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal Transduction
Chow, J. C., Young, D. W., Golenbock, D. T., Christ, W. J., & Gusovsky, F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.10689 · Cited by 1,924
Ferrario, C. M., Jessup, J., Chappell, M. C., Averill, D. B., Brosnihan, K. B., Tallant, E. A., Diz, D. I., & Gallagher, P. E. (2005) · Circulation · doi:10.1161/circulationaha.104.510461 · Cited by 1,565
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · cited 1×
“However, since neutralising antibodies against SARS-CoV-2 have been shown to decline over a period of only 3 months postinfection in humans [13], there is a need to adopt a parallel treat-ment strategy that involves the innate immune system, besides antiviral drugs.”
Imai, Y., Kuba, K., Neely, G. G., Yaghubian-Malhami, R., Perkmann, T., van Loo, G., Ermolaeva, M., Veldhuizen, R., Leung, Y. H. C., Wang, H., et al. (2008) · Cell · doi:10.1016/j.cell.2008.02.043 · Cited by 1,356
Interferon-stimulated genes and their antiviral effector functions
Schoggins, J. W., & Rice, C. M. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.10.008 · Cited by 1,289
TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β
Kagan, J. C., Su, T., Horng, T., Chow, A., Akira, S., & Medzhitov, R. (2008) · Nature Immunology · doi:10.1038/ni1569 · Cited by 1,253
Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1729069 · Cited by 1,252
Chen, L., Li, X., Chen, M., Feng, Y., & Xiong, C. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa078 · Cited by 1,163 · cited 1×
“ACE2 was found to be expressed in multiple cells in the heart: cardiomyocytes and mural cells, particularly pericytes which may act as the initial target cells and result in endothelial and microvascular dysfunction [53, 54].”
Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., & Doerr, H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13615-x · Cited by 1,158
Ahmed, S. F., Quadeer, A. A., & McKay, M. R. (2020) · Viruses · doi:10.3390/v12030254 · Cited by 1,116
CD14 Controls the LPS-Induced Endocytosis of Toll-like Receptor 4
Zanoni, I., Ostuni, R., Marek, L. R., Barresi, S., Barbalat, R., Barton, G. M., Granucci, F., & Kagan, J. C. (2011) · Cell · doi:10.1016/j.cell.2011.09.051 · Cited by 997
Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients
Zhou, Z., Ren, L., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., Guo, L., Yang, J., Wang, C., Jiang, S., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.017 · Cited by 938
Yang, H., Hreggvidsdottir, H. S., Palmblad, K., Wang, H., Ochani, M., Li, J., Lu, B., Chavan, S., Rosas-Ballina, M., Al-Abed, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003893107 · Cited by 809
Akhmerov, A., & Marbán, E. (2020) · Circulation Research · doi:10.1161/circresaha.120.317055 · Cited by 693
Ramamoorthy, S., & Cidlowski, J. A. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.08.002 · Cited by 692
Clinical characteristics of 82 cases of death from COVID-19
Zhang, B., Zhou, X., Qiu, Y., Song, Y., Feng, F., Feng, J., Song, Q., Jia, Q., & Wang, J. (2020) · PLOS ONE · doi:10.1371/journal.pone.0235458 · Cited by 683
Soesatyo, M. H. (2012) · Jurnal Teknosains · doi:10.22146/teknosains.5992 · Cited by 652
Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium
Frantz, S., Kobzik, L., Kim, Y.-D., Fukazawa, R., Medzhitov, R., Lee, R. T., & Kelly, R. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6709 · Cited by 645
TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis
Kuzmich, N., Sivak, K., Chubarev, V., Porozov, Y., Savateeva-Lyubimova, T., & Peri, F. (2017) · Vaccines · doi:10.3390/vaccines5040034 · Cited by 633
Matsunaga, N., Tsuchimori, N., Matsumoto, T., & Ii, M. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.068064 · Cited by 597
Pathogenesis of influenza-induced acute respiratory distress syndrome
Short, K. R., Kroeze, E. J. B. V., Fouchier, R. A. M., & Kuiken, T. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70286-x · Cited by 538
Grandvaux, N., Servant, M. J., tenOever, B., Sen, G. C., Balachandran, S., Barber, G. N., Lin, R., & Hiscott, J. (2002) · Journal of Virology · doi:10.1128/jvi.76.11.5532-5539.2002 · Cited by 519
ACE2: from vasopeptidase to SARS virus receptor
Turner, A. J., Hiscox, J. A., & Hooper, N. M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.04.001 · Cited by 517
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*
Rice, T. W., Wheeler, A. P., Bernard, G. R., Vincent, J.-L., Angus, D. C., Aikawa, N., Demeyer, I., Sainati, S., Amlot, N., Cao, C., et al. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181e7c5c9 · Cited by 512
COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
TUFAN, A., AVANOĞLU GÜLER, A., & MATUCCI-CERINIC, M. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-168 · Cited by 495
Choudhury, A., & Mukherjee, S. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25987 · Cited by 488
Peng, Y., Meng, K., Guan, H., Leng, L., Zhu, R., Wang, B. Y., He, M. A., Cheng, L., Huang, K., & Zeng, Q. (2020) · PubMed · doi:10.3760/cma.j.cn112148-20200220-00105 · Cited by 469
Totura, A. L., Whitmore, A., Agnihothram, S., Schäfer, A., Katze, M. G., Heise, M. T., & Baric, R. S. (2015) · mBio · doi:10.1128/mbio.00638-15 · Cited by 455
The Role of Toll-Like Receptor 4 in Infectious and Noninfectious Inflammation
Molteni, M., Gemma, S., & Rossetti, C. (2016) · Mediators of Inflammation · doi:10.1155/2016/6978936 · Cited by 446
Tissue-Specific mRNA Expression Profiles of Human Toll-Like Receptors and Related Genes
Nishimura, M., & Naito, S. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.886 · Cited by 443
The TLR4 antagonist Eritoran protects mice from lethal influenza infection
Shirey, K. A., Lai, W., Scott, A. J., Lipsky, M., Mistry, P., Pletneva, L. M., Karp, C. L., McAlees, J., Gioannini, T. L., Weiss, J., et al. (2013) · Nature · doi:10.1038/nature12118 · Cited by 423
Surfactant Replacement Therapy for Preterm and Term Neonates With Respiratory Distress
Polin, R. A., Carlo, W. A., COMMITTEE ON FETUS AND NEWBORN, Papile, L.-A., Polin, R. A., Carlo, W., Tan, R., Kumar, P., Benitz, W., Eichenwald, E., et al. (2014) · Pediatrics · doi:10.1542/peds.2013-3443 · Cited by 413
TLR2 and TLR4 mediated host immune responses in major infectious diseases: a review
Mukherjee, S., Karmakar, S., & Babu, S. P. S. (2016) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2015.10.011 · Cited by 410
Type III interferons disrupt the lung epithelial barrier upon viral recognition
Broggi, A., Ghosh, S., Sposito, B., Spreafico, R., Balzarini, F., Lo Cascio, A., Clementi, N., De Santis, M., Mancini, N., Granucci, F., et al. (2020) · Science · doi:10.1126/science.abc3545 · Cited by 402
Cameron, M. J., Ran, L., Xu, L., Danesh, A., Bermejo-Martin, J. F., Cameron, C. M., Muller, M. P., Gold, W. L., Richardson, S. E., Poutanen, S. M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.00527-07 · Cited by 386
TLR2 and TLR4 in Autoimmune Diseases: a Comprehensive Review
Liu, Y., Yin, H., Zhao, M., & Lu, Q. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-013-8402-y · Cited by 365
Guillot, L., Medjane, S., Le-Barillec, K., Balloy, V., Danel, C., Chignard, M., & Si-Tahar, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305790200 · Cited by 359
A candidate multi-epitope vaccine against SARS-CoV-2
Kar, T., Narsaria, U., Basak, S., Deb, D., Castiglione, F., Mueller, D. M., & Srivastava, A. P. (2020) · Scientific Reports · doi:10.1038/s41598-020-67749-1 · Cited by 349
Timmers, L., Sluijter, J. P. G., van Keulen, J. K., Hoefer, I. E., Nederhoff, M. G. J., Goumans, M.-J., Doevendans, P. A., van Echteld, C. J. A., Joles, J. A., Quax, P. H., et al. (2008) · Circulation Research · doi:10.1161/circresaha.107.158220 · Cited by 344
The emerging role of Toll-like receptor 4 in myocardial inflammation
Yang, Y., Lv, J., Jiang, S., Ma, Z., Wang, D., Hu, W., Deng, C., Fan, C., Di, S., Sun, Y., et al. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.140 · Cited by 337
Early innate immune responses to bacterial LPS
Rosadini, C. V., & Kagan, J. C. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.10.005 · Cited by 323
Mechanisms of Disease: Toll-like receptors in cardiovascular disease
Frantz, S., Ertl, G., & Bauersachs, J. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0938 · Cited by 312
Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts
Nicin, L., Abplanalp, W. T., Mellentin, H., Kattih, B., Tombor, L., John, D., Schmitto, J. D., Heineke, J., Emrich, F., Arsalan, M., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa311 · Cited by 289
Inhibition of Toll-like Receptor 4 With Eritoran Attenuates Myocardial Ischemia-Reperfusion Injury
Shimamoto, A., Chong, A. J., Yada, M., Shomura, S., Takayama, H., Fleisig, A. J., Agnew, M. L., Hampton, C. R., Rothnie, C. L., Spring, D. J., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.000901 · Cited by 284
Calcium signaling and mitochondrial destabilization in the triggering of the NLRP3 inflammasome
Horng, T. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.02.007 · Cited by 278
Respiratory Syncytial Virus Up-regulates TLR4 and Sensitizes Airway Epithelial Cells to Endotoxin
Monick, M. M., Yarovinsky, T. O., Powers, L. S., Butler, N. S., Carter, A. B., Gudmundsson, G., & Hunninghake, G. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308093200 · Cited by 276
Toll-Like Receptor Signaling and Its Inducible Proteins
Satoh, T., & Akira, S. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0040-2016 · Cited by 273
Enayatkhani, M., Hasaniazad, M., Faezi, S., Gouklani, H., Davoodian, P., Ahmadi, N., Einakian, M. A., Karmostaji, A., & Ahmadi, K. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1756411 · Cited by 250
Diagnosis and Treatment of Viral Myocarditis
Schultz, J. C., Hilliard, A. A., Cooper, L. T., & Rihal, C. S. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60670-8 · Cited by 246
Haeberle, H. A., Takizawa, R., Casola, A., Brasier, A. R., Dieterich, H., van Rooijen, N., Gatalica, Z., & Garofalo, R. P. (2002) · The Journal of Infectious Diseases · doi:10.1086/344644 · Cited by 237
Fairweather, D., Yusung, S., Frisancho, S., Barrett, M., Gatewood, S., Steele, R., & Rose, N. R. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.9.4731 · Cited by 229
Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?
Andersson, U., Ottestad, W., & Tracey, K. J. (2020) · Molecular Medicine · doi:10.1186/s10020-020-00172-4 · Cited by 229
Expression of Functional Toll-Like Receptor-2 and -4 on Alveolar Epithelial Cells
Armstrong, L., Medford, A. R. L., Uppington, K. M., Robertson, J., Witherden, I. R., Tetley, T. D., & Millar, A. B. (2004) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0078oc · Cited by 228
Turner, N. A. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.11.002 · Cited by 216
Zhu, H., Rhee, J.-W., Cheng, P., Waliany, S., Chang, A., Witteles, R. M., Maecker, H., Davis, M. M., Nguyen, P. K., & Wu, S. M. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01292-3 · Cited by 210
Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction
Vilahur, G., Juan-Babot, O., Peña, E., Oñate, B., Casaní, L., & Badimon, L. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.12.021 · Cited by 209
MyD88 Is Required for Protection from Lethal Infection with a Mouse-Adapted SARS-CoV
Sheahan, T., Morrison, T. E., Funkhouser, W., Uematsu, S., Akira, S., Baric, R. S., & Heise, M. T. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000240 · Cited by 207
Ye, R., & Liu, Z. (2020) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.104350 · Cited by 205
Su, Q., Li, L., Sun, Y., Yang, H., Ye, Z., & Zhao, J. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000490866 · Cited by 204
Pulmonary Surfactant: An Immunological Perspective
Chroneos, Z., Sever-Chroneos, Z., & Shepherd, V. (2010) · Cellular Physiology and Biochemistry · doi:10.1159/000272047 · Cited by 203
Alveolar lipids in pulmonary disease. A review
Agudelo, C. W., Samaha, G., & Garcia-Arcos, I. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01278-8 · Cited by 202
Make Yourself at Home: Viral Hijacking of the PI3K/Akt Signaling Pathway
Diehl, N., & Schaal, H. (2013) · Viruses · doi:10.3390/v5123192 · Cited by 200
Toll-like receptor 4 in acute viral infection: Too much of a good thing
Olejnik, J., Hume, A. J., & Mühlberger, E. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007390 · Cited by 200
Sohn, K. M., Lee, S.-G., Kim, H. J., Cheon, S., Jeong, H., Lee, J., Kim, I. S., Silwal, P., Kim, Y. J., Paik, S., et al. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e343 · Cited by 199
Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach
Samad, A., Ahammad, F., Nain, Z., Alam, R., Imon, R. R., Hasan, M., & Rahman, M. S. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1792347 · Cited by 191
Fu, J., Zhou, B., Zhang, L., Balaji, K. S., Wei, C., Liu, X., Chen, H., Peng, J., & Fu, J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05478-4 · Cited by 189
Fuse, K., Chan, G., Liu, Y., Gudgeon, P., Husain, M., Chen, M., Yeh, W.-C., Akira, S., & Liu, P. P. (2005) · Circulation · doi:10.1161/circulationaha.105.536433 · Cited by 181
The Role of TLR2, TLR4, and TLR9 in the Pathogenesis of Atherosclerosis
Roshan, M. H. K., Tambo, A., & Pace, N. P. (2016) · International Journal of Inflammation · doi:10.1155/2016/1532832 · Cited by 175
Tarassishin, L., Suh, H.-S., & Lee, S. C. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-187 · Cited by 169
Rahman, M. S., Hoque, M. N., Islam, M. R., Akter, S., Rubayet-Ul-Alam, A., Siddique, M. A., Saha, O., Rahaman, M. M., Sultana, M., Crandall, K. A., et al. (2020) · PeerJ · doi:10.7717/peerj.9572 · Cited by 166
Immunomodulatory activity of interferon‐beta
Kasper, L. H., & Reder, A. T. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.84 · Cited by 159
Innate immune receptor Toll-like receptor 4 signalling in neuropsychiatric diseases
García‐Bueno, B., Caso, J. R., Madrigal, J. L. M., & Leza, J. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.013 · Cited by 159
Kuronuma, K., Mitsuzawa, H., Takeda, K., Nishitani, C., Chan, E. D., Kuroki, Y., Nakamura, M., & Voelker, D. R. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.040832 · Cited by 156
Li, C. (2003) · Cardiovascular Research · doi:10.1016/j.cardiores.2003.09.007 · Cited by 156
Luo, Y., Jiang, L., Kang, K., Fei, D., Meng, X., Nan, C., Pan, S., Zhao, M., & Zhao, M. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.02.017 · Cited by 152
Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload
HA, T., LI, Y., HUA, F., MA, J., Gao, X. J., Kelley, J., Zhao, A. T., Haddad, G. E., WILLIAMS, D., & WILLIAMBROWDER, I. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.05.025 · Cited by 152
Reading the viral signature by Toll-like receptors and other pattern recognition receptors
Mogensen, T. H., & Paludan, S. R. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0620-6 · Cited by 149
Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?
Murck, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01239 · Cited by 145
Martino, T. A., Petric, M., Weingartl, H. M., Bergelson, J. M., Opavsky, M. A., Richardson, C. D., Modlin, J. F., Finberg, R. W., Kain, K. C., Willis, N. G., et al. (2000) · Virology · doi:10.1006/viro.2000.0324 · Cited by 144
TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung
Bhattacharyya, S., Wang, W., Qin, W., Cheng, K., Coulup, S. K., Chavez, S. A., Jiang, S., Raparia, K., de Almeida, L., Stehlik, C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98850 · Cited by 141
He, X., Qian, Y., Li, Z., Fan, E., Li, Y., Wu, L., Billiar, T. R., Wilson, M. A., Shi, X., & Fan, J. (2016) · Scientific Reports · doi:10.1038/srep31663 · Cited by 136
Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by a Retrovirus
Burzyn, D., Rassa, J. C., Kim, D., Nepomnaschy, I., Ross, S. R., & Piazzón, I. (2003) · Journal of Virology · doi:10.1128/jvi.78.2.576-584.2004 · Cited by 132
The interplay between Angiotensin II, TLR4 and hypertension
Biancardi, V. C., Bomfim, G. F., Reis, W. L., Al-Gassimi, S., & Nunes, K. P. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.017 · Cited by 128
Targeting human TLRs to combat COVID‐19: A solution?
Patra, R., Das, N. C., & Mukherjee, S. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26387 · Cited by 120
Toll-like receptors in cardiovascular diseases
DEKLEIJN, D., & Pasterkamp, G. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(03)00348-1 · Cited by 117
MacRedmond, R. E., Greene, C. M., Taggart, C. C., McElvaney, N. G., & O'Neill, S. J. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-116 · Cited by 109
Zhang, W., Xu, X., Kao, R. L. C., Mele, T. S., Kvietys, P. R., Martin, C. M., & Rui, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107639 · Cited by 106
Zou, N., Ao, L., Cleveland, J. C., Yang, X., Su, X., Cai, G.-Y., Banerjee, A. M., Fullerton, D. A., & Meng, X. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00299.2008 · Cited by 103
Birks, E., Felkin, L., Banner, N., Khaghani, A., Barton, P., & Yacoub, M. (2004) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(03)00106-2 · Cited by 102
Wang, Y., & Liu, L. (2016) · mBio · doi:10.1128/mbio.01872-15 · Cited by 95
Brandão, S. C. S., Ramos, J. D. O. X., Dompieri, L. T., Godoi, E. T. A. M., de Figueiredo, J. L., SARINHO, E. S. C., Chelvanambi, S., & Aikawa, M. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.09.002 · Cited by 94
Phospholipid regulation of innate immunity and respiratory viral infection
Voelker, D. R., & Numata, M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.aw118.003229 · Cited by 86
Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases
Patra, M. C., Shah, M., & Choi, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.002 · Cited by 85
Abate, W., Alghaithy, A. A., Parton, J., Jones, K. P., & Jackson, S. K. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m000513 · Cited by 82
Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection
Iampietro, M., Younan, P. M., Nishida, A., Dutta, M., Lubaki, N. M., Santos, R. I., Koup, R. A., Katze, M. G., & Bukreyev, A. A. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006397 · Cited by 82
TRIF Is a Critical Survival Factor in Viral Cardiomyopathy
Riad, A., Westermann, D., Zietsch, C., Savvatis, K., Becher, P. M., Bereswill, S., Heimesaat, M. M., Lettau, O., Laßner, D., Dörner, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002029 · Cited by 80
Differential Response of Primary Alveolar Type I and Type II Cells to LPS Stimulation
Wong, M. H., & Johnson, M. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055545 · Cited by 79
Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Huber, S. A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151222160500 · Cited by 79
Platelet TLR4 at the crossroads of thrombosis and the innate immune response
Schattner, M. A. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0618-213r · Cited by 79
Bhattacharyya, S., Midwood, K. S., Yin, H. H., & Varga, J. (2017) · Advances in Wound Care · doi:10.1089/wound.2017.0732 · Cited by 78
Novel strategies for targeting innate immune responses to influenza
Shirey, K. A., Lai, W., Patel, M. C., Pletneva, L. M., Pang, C. J., Kurt‐Jones, E. A., Lipsky, M., Roger, T., Calandra, T., Tracey, K. J., et al. (2016) · Mucosal Immunology · doi:10.1038/mi.2015.141 · Cited by 77
The Toll-Like Receptor 4-Antagonist Eritoran Reduces Murine Cardiac Hypertrophy
Ehrentraut, H., Weber, C., Ehrentraut, S., Schwederski, M., Boehm, O., Knuefermann, P., Meyer, R., & Baumgarten, G. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr035 · Cited by 75
Rahman, N., Ali, F., Basharat, Z., Shehroz, M., Khan, M. K., Jeandet, P., Nepovimová, E., Kuča, K., & Khan, H. Z. (2020) · Vaccines · doi:10.3390/vaccines8030423 · Cited by 75
Diverse Functions of Pulmonary Collectins in Host Defense of the Lung
Ariki, S., Nishitani, C., & Kuroki, Y. (2012) · BioMed Research International · doi:10.1155/2012/532071 · Cited by 65
Kolomaznik, M., Nová, Z., & Čalkovská, A. (2017) · Physiological Research · doi:10.33549/physiolres.933672 · Cited by 64
Luo, M., Hu, L., Li, D., Wang, Y., He, Y., Zhu, L., & Ren, W. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.06.035 · Cited by 59
Detection of Severe Acute Respiratory Syndrome-Associated Coronavirus in Pneumocytes of the Lung
Chow, K., Hsiao, C.-H., Lin, T., Chen, C., & Chiou, S.-H. (2004) · American Journal of Clinical Pathology · doi:10.1309/c0ed-u0ra-qbtx-bhce · Cited by 54
Cellular and molecular mechanisms underlying LPS-associated myocyte impairment
Tavener, S. A., & Kubes, P. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00701.2005 · Cited by 53
Angiotensin-(1–7) and Vascular Function
Touyz, R. M., & Montezano, A. C. I. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.10406 · Cited by 53
Identification of the Receptor Binding Domain of the Mouse Mammary Tumor Virus Envelope Protein
Zhang, Y., Rassa, J. C., Obaldia, M. E. D., Albritton, L. M., & Ross, S. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.19.10468-10478.2003 · Cited by 51
Bacterial lipopolysaccharide promotes profibrotic activation of intestinal fibroblasts
Burke, J. P., Cunningham, M. F., Watson, R. W. G., Docherty, N. G., Coffey, J. C., & O’Connell, P. R. (2010) · British journal of surgery · doi:10.1002/bjs.7045 · Cited by 51
Thompson, M. T., Kliewer, A. L., Maass, D. L., Becker, L., White, D. J., Bryant, D. D., Arteaga, G. M., Horton, J. W., & Giroir, B. P. (2000) · Pediatric Research · doi:10.1203/00006450-200005000-00019 · Cited by 50
Effect of Toll-like receptor 4 inhibitor on LPS-induced lung injury
Seki, H., Tasaka, S., Fukunaga, K., Shiraishi, Y., Moriyama, K., Miyamoto, K., Nakano, Y., Matsunaga, N., Takashima, K., Matsumoto, T., et al. (2010) · Inflammation Research · doi:10.1007/s00011-010-0195-3 · Cited by 47
Psoriasis and extra domain A fibronectin loops
McFadden, J. P., Baker, B. S., Powles, A. V., & Fry, L. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.09737.x · Cited by 45
Ablation of Toll-like receptor 9 attenuates myocardial ischemia/reperfusion injury in mice
Kitazume-Taneike, R., Taneike, M., Omiya, S., Misaka, T., Nishida, K., Yamaguchi, O., Akira, S., Shattock, M. J., Sakata, Y., & Otsu, K. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.05.150 · Cited by 45
Khodir, A. E., Samra, Y. A., & Said, E. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117907 · Cited by 44
Liu, P. P., & Opavsky, M. A. (2000) · Circulation Research · doi:10.1161/01.res.86.3.253 · Cited by 42
McKeown‐Longo, P. J., & Higgins, P. J. (2017) · Advances in Wound Care · doi:10.1089/wound.2017.0736 · Cited by 37
Miocarditis in Patients with COVID-19 Confirmed by Immunohistochemical
Коган, Е. А., Berezovskiy, Y. S., Blagova, O. V., Kukleva, A., Bogacheva, G. A., Kurilina, E. V., Kalinin, D. V., Bаgdаsаryan, T. R., Semeyonova, L. A., Gretsov, E., et al. (2020) · Kardiologiia · doi:10.18087/cardio.2020.7.n1209 · Cited by 37
Herz in der Sepsis: Molekulare Mechanismen, Diagnose und Therapie der septischen Kardiomyopathie
Märtin, L., Derwall, M., Thiemermann, C., & Schürholz, T. (2017) · Der Anaesthesist · doi:10.1007/s00101-017-0329-x · Cited by 36
Toll-like receptor 4 promotes fibrosis in bleomycin-induced lung injury in mice
Li, X., Jiang, D., Huang, X., Guo, S. L., Yuan, W., & Dai, H. (2015) · Genetics and Molecular Research · doi:10.4238/2015.december.21.8 · Cited by 35
Yang, R., Song, Z., Wu, S., Wei, Z., Xu, Y., & Shen, X. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.10.018 · Cited by 35
Changes of Laboratory Cardiac Markers and Mechanisms of Cardiac Injury in Coronavirus Disease 2019
Li, L., Zhou, Q., & Xu, J. (2020) · BioMed Research International · doi:10.1155/2020/7413673 · Cited by 35
Toll-Like Receptor Signaling and Its Inducible Proteins
Satoh, T., & Akira, S. (2017) · ASM Press eBooks · doi:10.1128/9781555819194.ch24 · Cited by 30
Jain, A. (2020) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_280_20 · Cited by 29
Jia, H., Cui, J., Jia, X., Zhao, J., Feng, Y., Zhao, P., Zang, D., Yu, J., Zhao, T., Wang, H., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7825 · Cited by 23
Rameshrad, M., Maleki‐Dizaji, N., Vaez, H., Soraya, H., Nakhlband, A., & Garjani, A. (2015) · PubMed · doi:10.22034/iji.2015.16740 · Cited by 22
Exploration of surface glycoprotein to design multi-epitope vaccine for the prevention of Covid-19
Oladipo, E. K., Ajayi, A. F., Ariyo, O. E., Onile, O. S., Jimah, E. M., Ezediuno, L. O., Adebayo, O. I., Adebayo, E. T., Odeyemi, A. N., Oyeleke, M. O., et al. (2020) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2020.100438 · Cited by 22
Zhou, Y., Li, Y., & Mu, T. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00026 · Cited by 21
Cardioprotective Role for angiotensin-(1-7) and Angiotensin Converting Enzyme 2 in the Heart
Tallant, E. A., Ferrario, C. M., & Gallagher, P. E. (2006) · Future Cardiology · doi:10.2217/14796678.2.3.335 · Cited by 16
LIN, P.-P., Hsieh, Y.-M., Kuo, W., Lin, Y.-M., Yeh, Y., Lin, C., Tsai, F., Tsai, C., Tsai, C., & Huang, C. (2013) · The Chinese Journal of Physiology · doi:10.4077/cjp.2013.bab118 · Cited by 15
Qiu, Q., Yang, Z., Cao, F., Yang, C., Hardy, P., Yan, X., Yang, S., & Xiong, W. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111737 · Cited by 14
Ratajczak, W., Niedźwiedzka‐Rystwej, P., Tokarz–Deptuła, B., et al. (2017) · Acta Biochimica Polonica · doi:10.18388/abp.2016_1403 · Cited by 9
Cited by
Adamu, A., Li, S., Gao, F., & Xue, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1347987 · Cited by 564
Toll-like receptor 4 (TLR4) inhibitors: Current research and prospective
Zhang, Y., Liang, X., Bao, X., Xiao, W., & Chen, G. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114291 · Cited by 299
SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19
Gusev, E., Sarapultsev, A., Solomatina, L., & Chereshnev, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031716 · Cited by 281
Glial functions in the blood-brain communication at the circumventricular organs
Miyata, S. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.991779 · Cited by 66
Post-COVID-19 Parkinsonism and Parkinson’s Disease Pathogenesis: The Exosomal Cargo Hypothesis
Mysiris, D. S., Vavougios, G. D., Karamichali, E., Papoutsopoulou, S., Stavrou, V. T., Papayianni, E., Boutlas, S., Mavridis, T., Foka, P., Zarogiannis, S. G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179739 · Cited by 25
Metadata
- Authors
- Aboudounya, M. M., & Heads, R. J.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2021-01
- Volume
- 2021
- Issue
- 1
- Pages
- 8874339-8874339
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- OpenAlex
- W3122114103
- Cited by
- 346
- References
- 157
- FWCI
- 21.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
